Trusted Resources: Education
Scientific literature and patient education texts
Activity of Daily Living in Mucopolysaccharidosis IVA patients: Evaluation of Therapeutic Efficacy
source: Molecular genetics & genomic medicine
year: 2021
authors: Chen H,Khan S,Celik B,Suzuki Y,Ago Y,Tomatsu S
summary/abstract:Mucopolysaccharidosis IVA (MPS IVA, also called Morquio A syndrome) is caused by a deficiency of N-acetylglucosamine-6-sulfate sulfatase (GALNS) and results in skeletal dysplasia symptoms such as short stature and abnormal gait. Treatments include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), but the effects are limited depending on the age of initiation and clinical phenotype. Thus, this study aims to assess the effects of treatments on MPS IVA patients compared to untreated MPS IVA patients and an age-matched control group.
organization: University of Delaware, Newark, DE, USA.DOI: 10.1002/mgg3.1806
read more
BookmarkRelated Content
-
Hunter and Kingston’s StoryI have three sons. Hunter is my oldest, ...
-
I Want to Live in the Moment While There’s Still TimeMy daughter Abby has Sanfilippo syndrome...
-
National MPS SocietyThe National MPS Society exists to cure,...
-
Demographic, Clinical, and Ancestry Characterization of a Large Cluster of Mucopolysaccharidosis IV A in the Brazili...Mucopolysaccharidosis (MPS) IVA is a rar...
-
Disease Burden, Management Patterns and Multidisciplinary Clinical Approaches for Patients With MPS IVA and VI in Se...There is a paucity of real-world epidemi...
-
Canadian MPS Society – LinkedInThe Canadian Society for Mucopolysacchar...
-
The Ryan FoundationChildren with rare diseases are racing t...
Powered by
